Form 8-K - Current report:
SEC Accession No. 0001558370-24-016085
Filing Date
2024-12-09
Accepted
2024-12-09 08:01:01
Documents
15
Period of Report
2024-12-04
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mxct-20241204x8k.htm   iXBRL 8-K 42357
2 EX-99.1 mxct-20241204xex99d1.htm EX-99.1 16050
3 GRAPHIC mxct-20241204xex99d1001.jpg GRAPHIC 4538
  Complete submission text file 0001558370-24-016085.txt   195625

Data Files

Seq Description Document Type Size
4 EX-101.SCH mxct-20241204.xsd EX-101.SCH 3266
5 EX-101.LAB mxct-20241204_lab.xml EX-101.LAB 16580
6 EX-101.PRE mxct-20241204_pre.xml EX-101.PRE 10719
17 EXTRACTED XBRL INSTANCE DOCUMENT mxct-20241204x8k_htm.xml XML 5020
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40674 | Film No.: 241533894
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)